Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

byBenzinga Newsdesk

September 13, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

Omnicom Buys Grabarz & Partner, Boosting Presence In Germany

By Lekha Gupta

July 6, 12:47 PM

Omnicom Group Inc (NYSE: OMC) disclosed the buyout of Grabarz & Partner to boost its footprint in Germany.

AMZN

Price Over Earnings Overview: Duke Energy

By Benzinga Insights

September 7, 2:15 PM

In the current market session, Duke Energy Inc. (NYSE:DUK) price is at $89.53, after a 2.33% spike. However,…

DUK

Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary Q1 2024 Revenue Of $41M-$43M Vs $38.21M Est.

By Benzinga Newsdesk

April 2, 4:12 PM

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today

ADPT

Baird Maintains Outperform on Planet Fitness, Raises Price Target to $105

By Benzinga Newsdesk

February 24, 8:11 AM

Baird analyst Jonathan Komp maintains Planet Fitness (NYSE:PLNT) with a Outperform and raises the price target from $100 to $105.

PLNT

Guggenheim Downgrades Rubius Therapeutics to Neutral

Related Posts

Omnicom Buys Grabarz & Partner, Boosting Presence In Germany

Price Over Earnings Overview: Duke Energy

Adaptive Biotechnologies Provides Strategic Review Update And Announces Preliminary Q1 2024 Revenue Of $41M-$43M Vs $38.21M Est.

Baird Maintains Outperform on Planet Fitness, Raises Price Target to $105